Nidovirales Infections: Clinical Trials

4592 completed, 2146 unknown, 585 terminated, 403 withdrawn. 1958 Not applicable, 1511 Phase 2, 958 Phase 3, 721 Phase 1, 264 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	1958	Completed 1186, Unknown 438, Withdrawn 83, Recruiting 80, Terminated 79, Active not recruiting 48, Not yet recruiting 28, Enrolling by invitation 8, Suspended 8
Phase 2	1511	Completed 691, Unknown 334, Terminated 255, Withdrawn 139, Recruiting 41, Active not recruiting 27, Not yet recruiting 13, Suspended 8, Enrolling by invitation 3
Phase 3	958	Completed 426, Unknown 243, Terminated 149, Withdrawn 87, Recruiting 22, Active not recruiting 13, Suspended 11, Not yet recruiting 5, Enrolling by invitation 2
Phase 1	721	Completed 402, Unknown 149, Terminated 71, Withdrawn 56, Recruiting 20, Active not recruiting 14, Not yet recruiting 9
Phase 4	264	Completed 121, Unknown 83, Terminated 26, Withdrawn 14, Active not recruiting 7, Recruiting 7, Not yet recruiting 3, Suspended 3
Early Phase 1	65	Unknown 24, Completed 23, Terminated 6, Withdrawn 5, Suspended 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1

Follow Nidovirales Infections: new trials by email Literature Review of Nidovirales Infections trials Research Report on Nidovirales Infections

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Perceptions of Undergraduate Students and Teaching Staff on Online Teaching Questionnaire - Covid19		Suspended	Misr International University	9209	2027-07-15	2026-10-08
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19	Phase 1 / Phase 2	Not yet recruiting	Kimera Labs Inc.	64	2027-01-01	2026-06-24
Taurine Supplementation in Adolescents With Post-COVID Condition Taurine - Long COVID, Post COVID-19 Condition	Phase 1 / Phase 2	Not yet recruiting	University of Alberta	30	2026-12-30	2026-10-16
CD19-B Cell Depletion in PAIS-ME/CFS Patients Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID)	Phase 2	Not yet recruiting	Charite University, Berlin, Germany	38	2026-12-01	2026-07-24
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS AVM0703, Placebo - ARDS, Covid19	Phase 1	Not yet recruiting	AVM Biotechnology Inc	16	2026-12-01	2025-10-02
Fatigue in Long COVID Lightning Process, Activity Pacing - Long COVID	Not applicable	Not yet recruiting	McMaster University	100	2026-11-01	2026-07-13
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test Flu A/B/COVID-19 + RSV Multiplex Rapid Test - SARS-CoV-2 Infection, Influenza A	Not applicable	Not yet recruiting	CorDx, Inc.	1500	2026-11-01	2026-10-15
Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region Vaccination Coverage Among Pregnant Women		Not yet recruiting	Assistance Publique - Hôpitaux de Paris	1605	2026-11-01	2026-10-20
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) Keytruda - Post-Acute COVID-19 Syndrome	Phase 1	Not yet recruiting	National Institute of Neurological Disorders and Stroke (NINDS)	15	2026-10-27	2026-10-22
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations mRNA-1273, mRNA-1283 - SARS-CoV-2	Phase 4	Not yet recruiting	ModernaTX, Inc.	300	2026-10-09	2026-10-07
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE) Aripiprazole (low-dose, 1mg), Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)	Phase 2	Not yet recruiting	Christiana Franke	138	2026-10-01	2026-07-20
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study Cryotherapy - ME/CFS, Fibromyalgia (FM)	Not applicable	Not yet recruiting	Oxford Brookes University	40	2026-10-01	2026-10-14
ELderly REspiratory VIral Cohort Respiratory viral infection - Influenza Viruses, Respiratory Syncytial Virus (RSV)		Not yet recruiting	Assistance Publique - Hôpitaux de Paris	1000	2026-10-01	2026-09-10
Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M - COVID-19	Phase 4	Recruiting	Sanofi	660	2026-10-01	2026-10-15
Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI) Respiratory Tract Infection, Smell Disorder		Recruiting	National Institute on Deafness and Other Communication Disorders (NIDCD)	80	2026-10-01	2026-10-09
Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years BMI2012 low-dose, Placebo low-dose, BMI2012 mid-dose - Prevention of COVID-19 Variant (Omicron JN.1)	Phase 1	Not yet recruiting	BMI Korea	72	2026-10-01	2026-08-28
Flu COVID Vaccine Views Survey - Influenza, COVID-19		Not yet recruiting	George Washington University	550	2026-10-01	2026-10-13
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine RVX-sCPD9 - COVID -19	Phase 1	Not yet recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	80	2026-09-26	2026-10-16
Transcranial Direct Current Stimulation for Long COVID Brain Fog and Fatigue Transcranial Direct Current Stimulation - Long COVID, Post-COVID Conditions	Not applicable	Not yet recruiting	University of Las Palmas de Gran Canaria	20	2026-09-15	2026-07-22
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease Secutrelvir, Placebo - SARS-CoV-2	Phase 3	Recruiting	Shionogi	2000	2026-09-14	2026-10-09

Showing 20 of 8354. Sign in to see all of them.

Narrower conditions

COVID-19 (7570)  ·  Coronavirus Infections (1111)  ·  Post-Acute COVID-19 Syndrome (597)  ·  Severe Acute Respiratory Syndrome (357)  ·  Respiratory Distress Syndrome (227)  ·  Pneumonia (221)  ·  Anxiety Disorders (182)  ·  Virus Diseases (150)  ·  Depression (133)  ·  Influenza, Human (125)  ·  Respiratory Insufficiency (124)  ·  Motor Activity (110)  ·  Pneumonia, Viral (109)  ·  Fatigue (95)  ·  Infections (89)

Broader conditions

Coronaviridae Infections (8326)  ·  RNA Virus Infections (8323)  ·  Infections (8265)  ·  Virus Diseases (8204)  ·  Respiratory Tract Diseases (8081)  ·  Respiratory Tract Infections (8003)  ·  Lung Diseases (7975)  ·  Pneumonia, Viral (7866)  ·  Pneumonia (7768)  ·  Coronavirus Infections (7243)  ·  Pathological Conditions, Signs and Symptoms (1614)  ·  Pathologic Processes (1288)  ·  Disease Attributes (910)  ·  Chronic Disease (663)

Interventions

Standard of Care (182)  ·  Hydroxychloroquine (175)  ·  Surveys and Questionnaires (119)  ·  Blood Specimen Collection (116)  ·  BNT162 Vaccine (110)  ·  Sodium Chloride (90)  ·  COVID-19 Vaccines (88)  ·  remdesivir (80)  ·  Saline Solution (79)  ·  2019-nCoV Vaccine mRNA-1273 (73)  ·  Ivermectin (70)  ·  Azithromycin (65)  ·  sinovac COVID-19 vaccine (57)  ·  Exercise (49)  ·  tocilizumab (49)

Sponsors

Assistance Publique - Hôpitaux de Paris (121)  ·  Assiut University (80)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (73)  ·  Pfizer (67)  ·  University Hospital, Strasbourg, France (58)  ·  University Hospital, Montpellier (44)  ·  Duke University (43)  ·  AstraZeneca (38)  ·  Cairo University (38)  ·  ModernaTX, Inc. (36)  ·  Ain Shams University (34)  ·  Hospices Civils de Lyon (32)  ·  Mayo Clinic (32)  ·  Stanford University (30)  ·  BioNTech SE (29)

Countries

United States (2013)  ·  France (806)  ·  China (453)  ·  Turkey (Türkiye) (439)  ·  Spain (437)  ·  Italy (398)  ·  United Kingdom (374)  ·  Brazil (338)  ·  Canada (311)  ·  Egypt (259)  ·  Germany (258)  ·  Mexico (204)  ·  Belgium (183)  ·  Russia (163)  ·  Argentina (128)

Top investigators

Mike Royal, MD (16)  ·  Adrian Hernandez, MD (9)  ·  Susanna Naggie, MD (8)  ·  Mikhail Samsonov (7)  ·  Neha Sharma (7)  ·  Sabine Hazan, MD (7)  ·  Tao Huang (7)

Results publications

PMID 34473343, PMID 35244208, PMID 31986264, PMID 35713300, PMID 32031570, PMID 32109013, PMID 32091533, PMID 32171076, PMID 34013969, PMID 36734509, PMID 37162745, PMID 33502773, PMID 36695483, PMID 34658014, PMID 37489818, PMID 37591523, PMID 32167524, PMID 34350582, PMID 32192578, PMID 32250385, PMID 32007143, PMID 32105632, PMID 32142651, PMID 33044747, PMID 33757717, PMID 38597249, PMID 33306989, PMID 33570583, PMID 36435633, PMID 32020029, PMID 32085846, PMID 32205204, PMID 32738928, PMID 33240091, PMID 33301246, PMID 34425070, PMID 35695334, PMID 39903535, PMID 15616839, PMID 21435708, PMID 27344959, PMID 31978945, PMID 31995857, PMID 32105637, PMID 32112977, PMID 32125452, PMID 32219428, PMID 32251768, PMID 32445440, PMID 32678530

NIH funding

2023 (21), U24TR001608 (8), 2025 (5), R25MH071584 (5), 1OT2HL156812-01 (4), P30CA033572 (4), OT2HL156812 (3), P30CA138292 (3), R01MD016328 (3), 1OT2HD107558-01 (2), 3UL1TR002538-03S2 (2), 3UM1AI068614-14S1 (2), 5UM1AI068614-14 (2), 5UM1AI148373-05 (2), 5UM1AI148684-02 (2)